Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Structure Therapeutics Inc GPCR

Healthcare
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE... see more

Recent & Breaking News (NDAQ:GPCR)

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

GlobeNewswire 11 days ago

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire 13 days ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

GlobeNewswire 13 days ago

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024 

GlobeNewswire October 31, 2024

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

GlobeNewswire September 17, 2024

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

GlobeNewswire August 27, 2024

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire August 26, 2024

Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire August 8, 2024

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

GlobeNewswire June 7, 2024

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

GlobeNewswire June 5, 2024

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

GlobeNewswire June 3, 2024

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

GlobeNewswire June 3, 2024

Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire May 9, 2024

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

GlobeNewswire March 8, 2024

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

GlobeNewswire March 8, 2024

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

GlobeNewswire December 18, 2023

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire November 14, 2023

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

GlobeNewswire September 29, 2023

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

GlobeNewswire September 29, 2023

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire August 10, 2023